Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Thierry André(Sorbonne Université), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Ming Lei(Bristol-Myers Squibb (United States)), Ka Yeung Mark Wong(Azienda Unita' Sanitaria Locale Di Modena), Arteid Memaj(Bristol-Myers Squibb (United States)), Sara Lonardi(Istituto Oncologico Veneto), Alain Hendlisz(Université Libre de Bruxelles), Andrew Hill(Trans Tasman Radiation Oncology Group), Fabio Gelsomino(University of Modena and Reggio Emilia), Michael B. Sawyer(Azienda Unita' Sanitaria Locale Di Modena), Bart Neyns(Molecular Oncology (United States)), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Massimo Aglietta(Candiolo Cancer Institute), Michael A. Morse(Azienda Unita' Sanitaria Locale Di Modena), H.J. Lenz(University of Southern California), Sandzhar Abdullaev(Bristol-Myers Squibb (United States)), Michael F. Dixon(Bristol-Myers Squibb (United States)), Ray McDermott(St. Vincent's University Hospital)
Cited by 253
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k